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Part of the heterodimeric P-TEF-b element of the Pol II transcription machinery, the cyclin-
dependent kinase 9 plays a critical role in gene expression. Phosphorylation of several
residues in the polymerase is required for elongation of transcript. It determines the rates
of transcription and thus, plays a critical role in several differentiation pathways, best docu-
mented in heart development.The synthesis and activity of the protein are tightly regulated
in a coordinated manner by at least three non-coding RNAs. First, its kinase activity is
reversibly inhibited by formation of a complex with the 334 nt 7SK RNA, from which it is
released under conditions of stress. Then, heart development requires a maximal rate of
synthesis during cardiomyocyte differentiation, followed by a decrease in the differenti-
ated state. The latter is insured by microRNA-mediated translational inhibition. In a third
mode of RNA control, increased levels of transcription are induced by small non-coding
RNA molecules with sequences homologous to the transcript. Designated paramutation,
this epigenetic variation, stable during development, and hereditarily transmitted in a non-
Mendelian manner over several generations, is thought to be a response to the inactivation
of one of the two alleles by an abnormal recombination event such as insertion of a
transposon.
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INTRODUCTION
Understanding the controls of gene expression by non-coding
RNAs, the major part of the “dark matter” of the genome (Kapra-
nov et al., 2010; Mattick et al., 2010), is becoming a major goal in
developmental biology, physiology, and pathology. Several mech-
anisms of such control have been uncovered – and the list is
certainly not complete. Our current work is focused on a net-
work involving at least three distinct small non-coding (snc)
RNAs, which work synergistically to adjust the levels of synthe-
sis and activity of a pleiotropic protein, the cyclin-dependent
kinase 9 (Cdk9), part of the heterodimeric complex designated
P-TEFb. Its serine–threonine kinase activity plays an essential role
in RNA polymerase II transcription and is currently recognized
as a critical actor in a number of physiological and pathologi-
cal processes. It is therefore understandable that both synthesis
and activity of Cdk9 are tightly regulated. The control of its
translation, critical in heart differentiation, is exerted by several
microRNAs, primarily miR-1 and miR-133. Its enzymatic activ-
ity is independently regulated by formation of a complex with
a 332 nt non-coding RNA, 7SK, which promotes the reversible
integration of protein inhibitors in P-TEFb. A third avenue of
regulation is via activation of transcription by sequence-related
oligoribonucleotides that we reported for Cdk9 and two other
genes (Rassoulzadegan et al., 2006; Wagner et al., 2008; Grandjean
et al., 2009).
Cdk9, A PROTEIN AT A NODAL POINT IN DEVELOPMENT AND
DIFFERENTIATION
The Cdk9 protein is associated with a cyclin from either the T
or the K families in the heterodimer P-TEFb, which plays a key
role in the Polymerase II transcription machinery (Kohoutek,
2009). The Cdk9 component functions as the catalytic domain,
while the cyclin constitutes the regulatory subunit (Malumbres
and Barbacid, 2005). P-TEFb is required after binding of the
initiation complex to a promoter – the phosphorylation of a C-
terminal domain of the polymerase by P-TEFb allows elongation
of the nascent transcript. Levels of transcription are therefore
determined by the recruitment of P-TEFb to promoters, in turn
dependent on its interactions with other proteins such as the bro-
modomain protein Brd4 (Yang et al., 2005). Cdk9 is also part of the
p300/GATA4 complex required for the expression of cardiac spe-
ciﬁc genes such as Nkx2.5, Anf, and ß-Myh (Kaichi et al., 2011
and references therein). P-TEFb interacts with Myosin skeletal
muscle differentiation (Simone et al., 2002) and interactions were
documented with a plethora of transcription factors (Kohoutek,
2009). Phosphorylation of substrates other than RNA Pol II are
also likely to be important, for instance that of several sites in p53
(Radhakrishnan and Gartel, 2006). A role in the activation of qui-
escent B cells was reported (De Falco et al., 2008), and a general
function has been proposed in transcription coupled alternative
splicing (Barboric et al., 2009). While the P-TEFb complex as a
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whole is a functional kinase unit, its activity appears to be essen-
tially modulated by variations of the synthesis and/or activity of
the Cdk9 moiety. Several RNA-mediated regulatory circuits have
been identiﬁed. Our knowledge is still, however, incomplete, as
illustrated by the paucity of data on the differential expression of
the two isoforms encoded at theCdk9 locus and on their respective
functions. In addition to the ubiquitous 42 kDa protein, a 55-kDa
species transcribed from a distinct upstream promoter includes
an additional N-terminal sequence of 117 aminoacids (Giacinti
et al., 2008). Differential expression of the two proteins has been
reported in various cell types and conditions (reviewed inRomano
andGiordano,2008).Weobserved that the longer isoform, initially
not expressed in ES cells, is transcribed in the course of their dif-
ferentiation into beating cardiac cells (Hossein Ghanbarian et al.,
unpublished).
Variations in Cdk9 expression, hence on P-TEFb activity, are
associated with various diseases. Among them, cardiac hypertro-
phy was the most extensively documented. Cardiomyocyte differ-
entiation normally involves an increase in cell size that requires a
general activation of transcription together with that of the heart-
speciﬁc genes. The kinase is required in normal differentiation and
its overexpression results in cardiac hypertrophy (Sano et al., 2002;
Wagner et al., 2008). Additional pathological developments are
associated with abnormal Cdk9 expression (Kohoutek, 2009). One
well-documented instance is viral immunodeﬁciency. A complex
of Cdk9 with the Tat proteins of HIV1 and HIV2 viruses enhances
their interaction with Tar RNA and thus, the transcription of the
viral genome (Wei et al., 1998). In human gastric tumors (He et al.,
2008), high levels of P-TEFb activity are generated by a mutation
deleting part of LARP7, a protein that participates in inhibition
of Cdk9 in the complex with 7SK RNA (see below). In addition
to the immunodeﬁciency family, other viruses of clinical interest
are dependent on the Cdk9 kinase, which therefore appears as a
likely target for the development of new pharmacological strate-
gies (reviewed by Romano and Giordano, 2008;Wang and Fischer,
2008).
MULTIPLE REGULATIONS BY SMALL NON-CODING RNAs
Given its essential functions, it is not unexpected that both the
synthesis and activity of the protein are under tight regulatory
controls. Three distinct circuits enacted by sncRNAs illustrate
their power and versatility. We will brieﬂy review the ﬁrst one,
translation control by microRNAs for which excellent reviews are
available (Kohoutek, 2009; Sayed and Abdellatif, 2011), and then
the reversible inhibition of enzymatic activity in the 7SK complex.
We will discuss in more detail the properties and possible function
of the inherited epigenetic increase in Cdk9 transcription in the
“Cdk9∗ paramutants” (Wagner et al., 2008).
DOWN REGULATION BY microRNA: THE CASE OF miR-1
Two of the microRNAs detected in heart (Callis and Wang, 2008)
have been the subject of intensive studies, miR-1 and miR-133.
miR-1, most important in heart development, targets the 3′
untranslated region of the Cdk9 transcript. In undifferentiated
ES cells, miR-1 is either absent or barely detectable. When car-
diac differentiation is induced by culture in suspension (Boheler
et al., 2002), expression progressively increases. Ectopic expression
in the initial ES cultures inhibits differentiation while reducing
expression of Cdk9 (Takaya et al., 2009). Forced expression of
miR-1 in embryonic cardiomyocytes inhibits their proliferation
and increases differentiation (Zhao et al., 2005). Down regulation
of Cdk9 is clearly critical to keep cardiac growth within the physio-
logical limits, and themicroRNAalso targetsHand2 mRNA,which
encodes a transcription factor required for ventricular myocyte
expansion. miR-1 and miR-133 play opposite roles in cardiomy-
ocyte growth and apoptosis. Unlike miR-1, which is apoptotic and
targets the anti-apoptotic heat shock proteins HSP60 and HSP70,
miR-133 is anti-apoptotic and represses caspase-9, a regulator of
mitochondria-mediated apoptosis (Xu et al., 2007). It is expected
that more miRNAs will be added to the growing list of cardiac
regulators (Callis and Wang, 2008).
REGULATION OF P-TEFb ENZYMATIC ACTIVITY: THE 7SK COMPLEX
A fraction of the Cdk9 protein is stored in a reversibly inactivated
form. Inhibition is achieved in a complex with the evolutionary
conserved 7SK sncRNA (Nguyen et al., 2001; Yang et al., 2001).
7SK bridges the protein to either one of two proteins, Hexim1 and
Hexim2, which inhibit the kinase activity (Yik et al., 2003; Byers
et al., 2005). In addition, two other proteins, MePCE and LARP7
are required for the stabilization of the complex by inhibiting
degradation of the 7SK RNA (Krueger et al., 2008). Complex for-
mation is fully reversible: its dissociation results in a burst of Cdk9
activity under conditions of stress, UV irradiation, mechanical
load, and pharmacological treatments by “hypertrophic agonists”
such as endothelin-1, phenylephrine, calcineurin (Nguyen et al.,
2001; Sano et al., 2002; Espinoza-Derout et al., 2009). As one
additional enzyme was found associated with 7SK complexes (He
et al., 2006), one may consider a more general type of regulation
by the means of readily reversible inhibition of enzyme activity
in complexes with inhibitory proteins mediated by non-coding
RNAs.
LONG TERM TRANSCRIPTIONAL ACTIVATION BY HOMOLOGOUS
OLIGORIBONUCLEOTIDES AND MICRORNAs
A third mode of regulation of Cdk9 expression directed by sncR-
NAs is epigenetic transcriptional activation during heart devel-
opment. It results in a dramatic heart hypertrophy syndrome
stably inherited over several generations (Wagner et al., 2008),
designated “paramutation” by analogy with the phenomenon of
plant hereditary epigenetic variations (Chandler, 2007). We pre-
viously reported a heritable epigenetic modiﬁcation of the Kit
gene induced by microinjecting mouse fertilized eggs with olig-
oribonucleotides with two types of sequences: (1) corresponding
to short stretches of the Kit transcript and (2) corresponding to
certain endogenous microRNAs (Rassoulzadegan et al., 2006). In
a quest for other examples, we practiced a series of injections of
other microRNAs and transcript fragments, among them oligori-
bonucleotides with a sequence from Cdk9 mRNA and the miR-1
microRNA. Their injection into one-cell embryos followed by
reimplantation in foster mothers resulted in increased expression
of Cdk9 in cardiomyocyte precursors at the E18.5 embryonic stage
(Wagner et al., 2008).
All the treated embryos developed into newborns and adults
showed increased heart size: 1.5- to 2-fold that of the controls,with
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a disrupted organization of the wall ultrastructure and TUNEL-
positive cells. All these features are characteristic of the human
hypertrophic cardiomyopathy, a severe condition with a poor
prognosis and, remarkably, a frequent familial distribution. In
the mouse, the cardiac phenotype was efﬁciently transmitted to
the offspring in three generations of crosses with normal part-
ners. Increased P-TEFb activity evidenced by Pol II phosphoryla-
tion resulted from elevated levels of Cdk9 mRNA resulting from
increased transcriptional activity. Levels of the Cyclin T1 and 7SK
RNAs remained unchanged.
Two remarkable features of the epigenetic variation are worth
noting. First, the Cdk9 gene remains subject to the same develop-
mental regulations as in the wild type controls. Overexpression, as
seen in the cardiomyocyte precursors (E18.5) andnormal develop-
ment, affects only the level of the short isoform exclusively made
in the wild type. The other remarkable feature, common to the
different instances of paramutation so far analyzed, is the mode of
inheritance described for other epigenetic variations as “rheostat
transmission” (Beaudet and Jiang, 2002). The quantitative pheno-
typicmodulation, in this case heart size, appears to be set separately
for every individual at some early time in development. In other
words, mice with large hearts will generate in the same litter ani-
mals with very large, large, more than average, and nearly normal
heart sizes. Conversely, mice with nearly normal or normal hearts
will generate the same assortment of phenotypes, including the
very large ones (Wagner et al., 2008). This pattern of phenotypic
distribution is more evocative of a continuous modulation such
as that of a rheostat than of the on–off “switch” of most genetic
controls.
LONG TERM ACTIVATION OF Cdk9 IN EMBRYONIC STEM
CELLS
With the aim to limit the complexity of the experimental approach,
we tested whether the same oligoribonucleotides would activate
transcription of Cdk9 in embryonic stem cells in culture (ES lines)
and affect their differentiation into cardiac precursors (Hossein
Ghanbarian and Minoo Rassoulzadegan, manuscript in prepara-
tion). In order to be able to compare the cell culture and in vivo
results,we made use of a mouse ES cell line that we have previously
tested for being able to successfully incorporate in the embryo
and give rise to whole spectrum of differentiated cell types. The
ﬁrst question was whether transcription of the genes paramutated
in the mouse would be increased to the same extent upon RNA
transfer by electroporation in ES cells and this turned out to be
the case. We were then able to compare these results with the
other instance of transcriptional activation by homologous RNAs,
recently reported in human cell lines in culture (Place et al., 2008;
Morris, 2009; Huang et al., 2010). A critical question was the sta-
bility of the activated state. Unlike the long term effects generated
in the mouse, the activated state in human cells was maintained
for only a limited number of cell doublings. Results in the ES
cells show a 1.5- to 2-fold activation of Cdk9 transcription within
the ﬁrst days in the transfected culture. Cotransfer of a selectable
marker allowed us to isolate clones maintaining elevated (1.5- to
3-fold) transcription rates, eventually reverting to the wild type
level, but only after their propagation in culture for 15–20 cell
generations. The ﬁeld of RNA paramutation will thus now beneﬁt
from the availability of a cell culture system to hopefully reach
a mechanistic explanation of RNA induction, an objective that
was obviously more difﬁcult to attain with the limited amounts of
material offered by early mouse embryos. Several lines of research
are now started on the cell culture system.One of them is a point by
point comparison with the short term induction of transcription
described in human cells. The two studies involved different genes
and the possible induction of Kit in human cells, for instance,
or paramutation of Cdh1 (E-cadherin), inducible in the mouse
(Huang et al., 2010), would allow more signiﬁcant comparisons.
An important mechanistic aspect is that in human cells, induction
requires the Argonaute system and mouse cells can now be tested
in this respect. One most intriguing aspect is the fact that, in ES
cells as in the mouse, oligoribonucleotides with fragments of the
sense sequence start the efﬁcient and highly speciﬁc paramutation
process. Recognition by base pairing would be the most obvious
explanation, leading to the assumption that natural antisense tran-
scripts are present in the cell. This class of non-coding RNAs has
been identiﬁed for various loci and their regulatory roles is cur-
rently a matter of attention in several laboratories (reviewed by
Werner and Swan, 2010).
The modiﬁed ES clones showed another property of interest
(Hossein Ghanbarian and Minoo Rassoulzadegan, manuscript in
preparation). The cells do not appear as even partially differen-
tiated. They express characteristic ES cell markers such as Nanog
(Silva et al., 2009) and none of the genes characteristic of car-
diomyocytes. Still, the epigenetic variation had conferred on the
cells the capacity to differentiate faster andmore efﬁciently into the
cardiac lineage. This was clearly ascertained when cardiac differ-
entiation was induced in the cultures (Boheler et al., 2002). Brieﬂy,
cells are ﬁrst grown in suspended aggregates, designated embryoid
bodies (“EB”), then EBs separately replated as individual small cul-
tures. Over the next days, cardiac marker genes are expressed with
a deﬁned time course, until eventually the appearance of rhythmi-
cally beating cardiac cells. They appeared at a much earlier time
and at higher frequencies in cultures of the Cdk9 paramutant
cells than in the control and the same was true of the expression
of cardiac markers such as the cardiac myosin genes. Interest-
ingly expression of Cdk9 in the differentiated cardiomyocytes had
returned to the value of the controls, as in the adult heart of the
paramutant mice (Wagner et al., 2008). Directing differentiation
of pluripotent stem cells to a differentiated state will be critical
for their intended use in therapeutic and regenerative medicine.
If generalized to other differentiation states, paramutation might
offer one possible approach to this goal. A similar result, based
on a different RNA-based technology, has been recently reported
(Warren et al., 2010).
DISTINCT REGULATIONS FOR DIFFERENT PHYSIOLOGICAL
SITUATIONS
An overall picture of Cdk9 regulation by sncRNAs, albeit still
incomplete and requiring further reﬁnement, is emerging from
these results. Under different physiological conditions, expres-
sion levels are set by distinct RNA-mediated regulatory pathways
summarized in Figure 1. During cardiac differentiation, involving
both cell growth and cell division, a general activation of tran-
scription is achieved only for a limited period, with continuing
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FIGURE 1 | Schematic representation of sncRNA-mediated
regulations of Cdk9 expression. (A) Down regulation by
microRNA miR-1 of Cdk9 translation in differentiated
cardiomyocytes following the high levels of expression required during the
differentiation process. (B) Storage of inactive protein in a complex with 7SK
RNA and inhibitory proteins, release of active kinase in stress conditions.
(C) Summary of our current observations on the initiation of paramutation.
Observed either in heterozygote genotypes with one allele disrupted by
insertion as in the case of Kit∗ paramutants (Rassoulzadegan et al., 2006) or
upon accumulation of a cognate microRNA, miR-1 in the case of Cdk9.
Abnormal RNAs have to be detected by a sensing system in the embryonic
cell. Suggestion that the sensor involves the RNAi machinery is based on our
current data showing a requirement for Argonaut proteins. Transcription is
then upregulated, possibly by a mechanism related to the RNA activation
process reported in human cells (Place et al., 2008; Morris, 2009; Huang
et al., 2010). As shown for miR-124 and the Sox9∗ paramutation (Grandjean
et al., 2009), heritability is explained by the transfer of the inducing RNAs by
oocyte and sperm (not shown).
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cell division leading to overgrowth and eventually to hypertro-
phy. Co-induction of miR-1 and other cardiac markers promotes
a progressive decline in Cdk9 synthesis. This is clearly only part
of the story and future work will surely make this simple scheme
more complex. The additional angle of RNA-mediated regulation
is tomake the storage of the protein in a reversibly inactivated state
respond to a distinct requirement of the system, namely to provide
an immediate burst of active enzyme under stress conditions.
Then, the possible “raison d’être” of the long term, hereditary
form of regulation of gene expression induced by short RNAs
with fragments of the sense sequence can only be at this stage a
matter of speculation. Coming back to the initial description of
the paramutation of the Kit gene (Rassoulzadegan et al., 2006),
it is important to note that the modiﬁcation was detected in the
progeny of heterozygotes carrying a gene disrupted by exogenous
sequences. Increased expression of the intact Kit+ allele in germ
cells was stably maintained during development and inherited in
serial crosses. Abnormal transcript fragments generated from the
disrupted allele appeared as the likely inducers of the epigenetic
change that led to the change in gene expression. Induction by the
cognate miRNAs (miR-221 and -222 for Kit,miR-1 for Cdk9,miR-
124 for Sox9) may result from the induction by the microRNAs of
degradation of the transcript into the inducing RNA fragments in
cells in which the miRNA is not normally present. Alternatively,
the ectopically expressed microRNAs may be acting as inducers by
themselves. Triggered by abnormal forms of the transcript, para-
mutation of the wild type locus may be, in teleonomic terms and
under natural circumstances, a way to compensate for the inac-
tivation of the other allele by a non-homologous recombination
event such as insertion of a transposon.
One important question iswhether paramutation couldbe con-
sidered as a general property of amouse gene – or its establishment
a general property of a miRNA. In addition to the consider-
ation that in this case, it should have been recognized a long
time ago, several observations clearly point to a negative answer.
No clear phenotype was generated in our hands by a series of
oligoribonucleotides tested in the microinjection assay and/or in
transfected ES cells. It is also signiﬁcant in this respect that miR-1
efﬁciently induced, both in the mouse and in ES cells, the long
term overexpression of Cdk9, but not of Hand2, a recognized tar-
get of the microRNA (Wagner et al., 2008). One may then have to
consider the process as characteristic of a subset of genes. It may
be noteworthy that all three genes for which paramutation events
have been detected, Kit, Cdk9, and Sox9, are critical for mouse
development to the point that homozygous negative mutants are
embryonic lethals. On a purely speculative basis, we would thus be
tempted to consider that we are dealing with a rescue mechanism,
offered to a limited number of loci, that compensates the defective
state of one locus by increasing the expression of the allelic wild
type gene.
Finally, one may wonder whether the biological processes
underlying the observations of “paramutation” are identical in
plants and in the mouse. Strictly speaking, they both follow Chan-
dler’s deﬁnition as “RNA-mediated instructions passed across
generations” (Chandler, 2007). The two processes appear, how-
ever, distinct in their most basic aspects – as distinct as mouse
is from maize. Primarily, the plant paramutation phenomenon
is a silencing process and the current thinking in the ﬁeld con-
siders RNA inducers, whose role was deduced from the require-
ments for plant-speciﬁc RNA polymerases, as guides for a DNA
methylation process (Simon and Meyers, 2011). In the mouse,
as discussed in the above sections, we and others reported, to
the contrary, a transcriptional activation induced by sequence-
related small RNAs – a clearly distinct process with, at the
present time, no established relationship to DNA methylation
(our unpublished data). Thus, a case can be made that a pos-
sible confusion is introduced by the use of the same word,
“paramutation,” to describe the two phenomena, a confusion
for which we are ourselves responsible for a signiﬁcant part. It
remains however that they have in common is the notion of
that heredity may not be circumscribed to the strict domain
of Mendelism, with possible important implications in mul-
tiple biological ﬁelds including pathology, developmental, and
evolutionary biology.
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